文献速递传染病防控与疫情报告免疫规划

德国2022年6月至2024年2月猴痘疫情期间疫苗安全性监测

Vaccine safety surveillance during an mpox outbreak, Germany, June 2022 to February 2024.
PubMed 文献 · Euro Surveill · 2026-01-01

该研究利用德国现有监测系统,对2022年6月至2024年2月猴痘疫情期间接种的Jynneos(MVA-BN)疫苗进行安全性评估。截至2024年2月29日,共报告3807例猴痘病例,接种78739剂疫苗,国家AEFI数据库识别32份个体病例安全性报告(其中7份严重),共87例不良事件,调整后报告率为每10万剂98.7例不良事件。结论认为该疫苗安全性特征与产品说明书一致,未发现新的安全信号。

要点

  • MVA-BN疫苗安全性特征与产品说明书一致,未发现新安全信号。
  • 调整后不良事件报告率为每10万剂98.7例,多为局部或全身反应。
  • 监测系统识别32份ICSRs,其中7份为严重报告,共87例不良事件。

核心结论

  • MVA-BN疫苗的安全性特征与产品说明书一致,未发现新的安全信号。

研究设计与样本

  • 利用德国现有监测系统(包括2022年6月实施的自愿猴痘疫苗接种监测)对2022年6月至2024年2月期间的猴痘病例、疫苗接种、个体病例安全性报告(ICSRs)和免疫接种后不良事件(AEFIs)进行描述性分析。

主要发现

  • 截至2024年2月29日,共报告3807例猴痘病例(数据检索于2024年7月)。
  • 根据自愿监测,共接种78739剂Jynneos猴痘疫苗。
  • 国家AEFI数据库识别32份ICSRs,其中7份为严重报告,共报告87例AEFIs,多为局部或全身反应。
  • 调整一个联邦州疫苗使用信息缺失后的总体不良事件报告率为每10万剂98.7例不良事件。

临床怎么用

  • 监测结果支持MVA-BN疫苗在猴痘疫情期间的安全性,接种时应关注常见局部和全身反应,严重不良事件罕见。

局限性

  • 自愿监测系统可能存在报告偏倚,且一个联邦州的疫苗使用信息缺失需调整报告率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDIn May 2022, first cases of mpox clade IIb were detected in Germany, and MVA-BN vaccine was available from June 2022 onwards. Vaccination has been recommended by the Standing Committee on Vaccination (STIKO) since June 2022 to contain monkeypox virus infection and prevent disease.AIMOur primary aim was to evaluate the safety of the mpox vaccine Jynneos (modified Vaccinia Ankara, Bavaria-Nordic, MVA-BN) after the rollout of the vaccination campaign in Germany from June 2022 to February 2024; a secondary aim was to describe mpox cases and vaccinations.METHODSTo identify cases and persons with adverse events following immunisation (AEFIs), we used existing surveillance systems. A voluntary system was implemented in June 2022 to monitor mpox vaccination. We performed a descriptive analysis of cases, vaccinations, individual case safety reports (ICSRs) and AEFIs.RESULTSUntil 29 February 2024, 3,807 mpox cases were notified (data retrieved July 2024). According to the voluntary mpox vaccination monitoring, a total of 78,739 mpox vaccine doses of Jynneos were administered. A search of the national AEFI database identified 32 ICSRs, of which seven were serious. A total of 87 AEFIs were reported, most of which were local or systemic reactions that are generally associated with vaccination. The overall adverse event reporting rate adjusted for missing information on vaccine utilisation in one of 16 federal states was 98.7 adverse events per 100,000 doses.CONCLUSIONThe safety profile of the MVA-BN vaccine was in line with the summary of product characteristics. No new safety signals were identified.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Oberle D, Hofmann A, Jansen K, et al. Vaccine safety surveillance during an mpox outbreak, Germany, June 2022 to February 2024. Euro Surveill. 2026. PMID: 42535289. doi:10.2807/1560-7917.ES.2026.31.30.2500843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。